PHARMACEUTICAL COMPOSITION FOR TREATING A MALIGNANT TUMOR, FLT3-POSITIVE, A FLT3 MUTANT INHIBITOR AND USE THEREOF Russian patent published in 2020 - IPC A61K31/505 A61P35/00 

FIELD: pharmaceuticals; medicine.

SUBSTANCE: first invention represents use of a pharmaceutical composition for treating a malignant tumor, mutation FLT3 positive, wherein the FLT3 mutation includes a TDK mutation containing a compound of general formula [1]

or a salt thereof. Also, the group of inventions includes use of said compound or its salt as inhibitor of mutant FLT3; method for predicting a therapeutic effect by administering said pharmaceutical composition to a subject which includes a step for detecting the presence or absence of a FLT3 mutation; method of selecting a subject, using said pharmaceutical composition, which includes a step for detecting presence or absence of mutation FLT3; and method of determining, whether or not said pharmaceutical composition is administered to a subject which includes a step for detecting the presence or absence of a FLT3 mutation.

EFFECT: group of inventions provides application of compounds and compositions possessing mutant FLT3 inhibition, in particular, with mutation TDK.

23 cl, 1 dwg, 5 tbl, 3 ex